Quality in Laboratory Hemostasis and Thrombosis

Dr Steve Kitchen, Clinical Scientist, Sheffield Hemophila and Thromobosis Centre, Royal Hallamshire Hospital and Scientific Director, UK National External Quality Assessment Scheme (FQAS) for Blood Coagulation, Scientific Director, WHO and WFH International External Quality Assessment Programs for Blood Coagulation, Sheffield, UK. John D Olson, Professor and Vice Chair for Clinical Affairs, Department of Pathology, University of Texas Health Sciences Centre, San Antonio, Texas, USA. F. Eric Preston, Emeritus Professsor of Hematology, University of Sheffield and Director, WHO and WFH International External Quality Assessment Programs for Blood Coagulations, Sheffield, UK.

Contributors, vii Foreword, x Preface, xii Steve Kitchen, John D. Olson, & F. Eric Preston Part 1: General Quality Program 1 General quality planning in the hemostasis laboratory, 3 John D. Olson 2 Hemostasis test validation, performance, and reference intervals: international recommendations and guidelines, 12 Richard A. Marlar 3 Causes of errors in medical laboratories, 22 Giuseppe Lippi & Emmanuel J. Favaloro 4 International standards in hemostasis, 32 Trevor W. Barrowcliffe & Anthony R. Hubbard 5 Sample integrity and preanalytical variables, 45 Dorothy (Adcock) Funk 6 Internal quality control in the hemostasis laboratory, 57 Steve Kitchen, F. Eric Preston, & John D. Olson 7 External quality assessment in hemostasis: its importance and significance, 65 F. Eric Preston, Steve Kitchen, & Alok Srivastava 8 The unique challenges of hemostatic testing in children, 77 M. Patricia Massicotte, Mary E. Bauman, Vanessa Chan, & Anthony K.C. Chan Part 2: Quality in Coagulation Testing 9 Initial evaluation of hemostasis: reagent and method selection, 95 Wayne L. Chandler 10 Assay of factor VIII and other clotting factors, 105 Steve Kitchen & F. Eric Preston 11 Application of molecular genetics to the investigation of inherited bleeding disorders, 115 Stefan Lethagen, Morten Duno, & Lars Bo Nielsen 12 Detecting and quantifying acquired functional inhibitors in hemostasis, 124 Bert Verbruggen, Myriam Dardikh, & Britta Laros-van Gorkom 13 Standardization of d-dimer testing, 136 Guido Reber & Philippe de Moerloose 14 Point-of-care testing in hemostasis, 147 Chris Gardiner, Dianne Kitchen, Samuel Machin, & Ian Mackie Part 3: Quality in Testing for Platelet Function and von Willebrand Disease 15 Diagnostic assessment of platelet function, 159 Paquita Nurden, Alan Nurden, & Martine Jandrot-Perrus 16 Laboratory evaluation of heparin-induced thrombocytopenia, 174 Theodore (Ted) E. Warkentin & Jane C. Moore 17 Laboratory evaluation of von Willebrand disease: phenotypic analysis, 192 Emmanuel J. Favaloro 18 Laboratory analysis of von Willebrand disease: molecular analysis, 204 Anne C. Goodeve & Ian R. Peake Part 4: Quality in Thrombophilia Testing and Monitoring Anticoagulation 19 Quality issues in heritable thrombophilia testing, 219 Isobel D. Walker & Ian Jennings 20 Evaluation of antiphospholipid antibodies, 233 Michael Greaves 21 Monitoring heparin therapy, 244 Marilyn Johnston 22 Monitoring oral anticoagulant therapy with vitamin K antagonists, 253 Armando Tripodi 23 Monitoring new anticoagulants, 264 Elaine Gray & Trevor W. Barrowcliffe Index, 273